Source: Annual Congress 2009 - Severe asthma and its treatment
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Kroegel, K. M. Stoiber, C. Kropf, S. Rüdiger, C. Heider, M. Foerster, A. Thielen, C. Schumann (Jena, Nürnberg, Ulm, Germany). Practice-related treatment of severe persistent bronchial asthma using omalizumab in Germany: the compliance and utilisation investigation under real-life-study (XCLUSIVE). Eur Respir J 2009; 34: Suppl. 53, 1872

Member's Comments

No comment yet.

Related content which might interest you: Long-term effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Real-life data from 3 UK centres Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Treatment of uncontrolled, severe persistent allergic (IgE-mediated) asthma with omalizumab in a real-life setting in Germany Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 ‘Real-life‘ persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study Source: Annual Congress 2011 - Asthma management and response Year: 2011 Predictors of severe asthma exacerbations, poor asthma control and beta-agonist overuse in adult asthma Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013 Which patients should be treated with anti-IgE? Source: Eur Respir Rev 2007; 16: 85-87 Year: 2007 Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy Source: Eur Respir Rev 2007; 16: 73-77 Year: 2007 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Pooled data from 4 UK centres Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 The use of omalizumab in the management of severe chronic paediatric asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Pooled data from 3 UK centres Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial Source: Eur Respir J 2007; 30: 457-466 Year: 2007 Real-life evaluation of budesonide/formoterol (DuoResp Spiromax) for the management of asthma and COPD in the UK Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD Year: 2017 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma Source: Eur Respir J 2008; 31: 982-989 Year: 2008 The influence of inhalation device for bronchodilators on the results of therapy in primary care patients with bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Asthma control or asthma severity Year: 2008 The role of adherence to inhaled corticosteroids (ICS) in the relationship between blood eosinophilia and asthma control Source: International Congress 2016 – Asthma management in primary care Year: 2016 Budesonid/formoterol easyhaler: clinical efficiency and adherence to treatment in patients with partly controlled bronchial asthma (BA). Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Influence of basic therapy of bronchial asthma (BA) on respiratory symptoms in patients with pulmonary TB associated with bronchial asthma Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1 Year: 2014 A pilot study of CPAP therapy for excessive dynamic airway collapse during acute exacerbation of COPD Source: International Congress 2014 – COPD - from biomarkers to novel therapeutic opportunities Year: 2014